Physician-Founded · Bangalore · Est. 2023
HAEMOSTATIC
INNOVATION
Next-generation haemostatic solutions for human surgery and veterinary care — engineered where passive technology fails.
2023
Founded
2+
Product Lines
CDSCO
Registered
ZL-HM01 · Active Agent
CDSCO · ISO 13485
ZICOSPON + ZL-HM01 Product Line
Haemostatic Innovation ◆
CDSCO Registered ◆
ISO 13485:2016 ◆
Physician-Founded ◆
Mumbai · India ◆
Active Hemostasis ◆
Veterinary Solutions ◆
CE Mark In-Process ◆
Haemostatic Innovation ◆
CDSCO Registered ◆
ISO 13485:2016 ◆
Physician-Founded ◆
Mumbai · India ◆
Active Hemostasis ◆
Veterinary Solutions ◆
CE Mark In-Process ◆
01
The Clinical Problem
Passive haemostatic agents fail in the most critical patients — those on anticoagulants, with thrombocytopenia, or with compromised coagulation. We built Zichor to solve that.
02
The Science
Our products work independently of the coagulation cascade, providing reliable haemostasis where conventional solutions consistently fall short. Validated in pre-clinical models.
03
The Standard
ISO 13485:2016 QMS. CDSCO registered. ISO 10993 biocompatible. Schedule M GMP. ISO 11137 sterility. We build to the same standards as the world's leading device companies.
What We Do
WHAT
WE
DO
Zichor Life Tech develops, manufactures, and commercialises next-generation haemostatic medical devices for human surgical and veterinary applications. Every product we make is built around a single principle: it must work for the patient you actually have in front of you — not the ideal patient the device was tested on.
We operate from a purpose-built clean-room manufacturing facility in Mumbai under a digital ISO 13485:2016 Quality Management System, with in-house analytical testing and a physician-led clinical development programme.
01
Active Haemostatic Agents
Coagulation-independent agents that initiate haemostasis at the wound surface regardless of the patient's clotting function. Currently in Phase I clinical evaluation.
02
Absorbable Haemostatic Sponges
ZICOSPON — our CDSCO-registered absorbable gelatin sponge for surgical haemostasis. Available in 4+ formats for standard and specialty procedures.
03
Veterinary Haemostatic Solutions
QURA-VET — purpose-designed haemostatic solutions for companion animal, equine, large animal, and exotic species surgery. 10 variants available.
04
Specialty Surgical Formats
Dental cubes, nasal tampons, anal tampons, laparoscopic strips, and ultra-thin films — engineered for the specific anatomical requirements of each procedure.
OUR
PRODUCTS
View All Products →
Active Agent · Human
01
ZL-HM01 Active Haemostatic Agent
Coagulation-independent haemostatic powder. Works in anticoagulated, thrombocytopenic, and coagulopathic patients where passive haemostats fail. Phase I clinical evaluation underway.
● Phase I Clinical
→
Absorbable Sponge · Human
02
ZICOSPON Absorbable Gelatin Sponge
CDSCO-registered sterile absorbable haemostatic sponge. Available in Standard, Regular, Special, and 12-7 formats. Fully resorbed within 4–6 weeks without retrieval.
● Commercially Available
→
Veterinary · Multi-Species
03
QURA-VET Haemostatic Sponge
Purpose-designed veterinary haemostatic sponge in 10 formats including Regular, Special, Dental Cubes, Nasal, Anal Tampon, and Film. For companion animals, equine, and large animal surgery.
● Commercially Available
→
CDSCORegistered Device
4–6WFull Resorption
10+Formats Available
ISO13485 Certified QMS
Why Zichor?
WHY
WE'RE
DIFFERENT
The haemostatic device market offers many solutions that perform well in routine patients. Zichor exists for the patients who are not routine — and for the surgeons who refuse to accept that haemostatic failure is inevitable when those patients are on the table.
01
Physician-Led. Not Investor-Led.
Every product decision at Zichor is made by clinicians who use the products — not investors optimising for exit. That keeps our roadmap honest.
02
Active Technology in Development
ZL-HM01 pursues coagulation-independent haemostasis — a category that does not yet exist commercially at scale. We are building the next generation, not iterating on the current one.
03
India-Made, International Standard
Clean-room manufacturing, ISO 13485 QMS, Schedule M GMP, ISO 10993 biocompatibility, ISO 11137 sterility. Built in India. Built to the world's highest standards.
04
Purpose-Built Veterinary Line
QURA-VET is not an adaptation of our human products. It is a dedicated veterinary platform built from the ground up for animal care — with the same rigour.
05
Transparent Evidence
We publish our pre-clinical data, share our clinical outcomes, and report our post-market surveillance findings openly. Surgeons deserve full transparency.
R&D Pipeline
RESEARCH
PIPELINE
4 active programmes · 1 in clinical phase
Coagulation-Independent HaemostasisPhase I Clinical
Topical Bioadhesive HaemostatsPre-Clinical
Trauma Packing SolutionsDevelopment
Biomarker-Guided HaemostasisDiscovery
Quality & Compliance
CERTIFICATIONS
& STANDARDS
Quality Management
ISO 13485:2016
Full QMS covering design, manufacture, and post-market surveillance.
Regulatory
CDSCO Registered
Class B medical device under India's Medical Devices Rules 2017.
Biocompatibility
ISO 10993
Full evaluation series — cytotoxicity, sensitisation, irritation, toxicity.
Sterility
ISO 11137
Radiation sterilisation validation. SAL 10⁻⁶ confirmed.
Manufacturing
Schedule M GMP
Revised Schedule M Good Manufacturing Practice compliance.
International
CE Mark — In Progress
CE marking under EU MDR 2017/745 actively being pursued.
LATEST UPDATES
View All Updates →Clinical · March 2025
Phase I Clinical Evaluation of ZL-HM01 Initiated at Partner Centre
First-in-human application of our active haemostatic agent has commenced at an academic medical centre. Primary endpoints: safety, tolerability, and preliminary haemostatic efficacy.
March 3, 2025
→
Blog · March 2025
Why Active Haemostasis Is the Next Frontier in Surgical Safety
For decades, surgeons have relied on passive haemostatic agents that work by concentrating the body's own clotting factors. But passive fails when the patient needs it most.
March 5, 2025
→
Regulatory · 2024
ZICOSPON Receives Full CDSCO Registration — Now Commercially Available
ZICOSPON has received its CDSCO registration as a Class B medical device under MDR 2017. First commercial units have been dispatched to partner surgical centres across India.
Q4 2024
→
GET IN
TOUCH
Surgeons · Distributors · Research Partners
Whether you are a surgeon looking to evaluate our products, a distributor exploring a partnership, or a research collaborator — we want to hear from you. Zichor is built on relationships with the people who use and understand what we make.